Dr Qianxin Wu

Dr Qianxin Wu is a Chinese-British biomedical scientist who has built an academic career at the intersection of single-cell genomics, advanced cell modelling, and therapeutic target discovery. Her research expertise, developed at the Wellcome Sanger Institute on the Wellcome Genome Campus in Cambridge, focuses on creating high-fidelity human disease models that can identify novel intervention points for autoimmune and fibrotic conditions.

Qianxin is Co-Founder and Head of Cell Models and Target Discovery at Ensocell, a Cambridge-based precision biologics company she co-founded in 2023 alongside Dr Sarah Teichmann, Dr Rasa Elmentaite, and Paul Gibson. At Ensocell she leads the development of the advanced cell models that underpin the company's ENSO AI platform, which integrates single-cell and spatial genomics data to identify molecular targets and predict disease biology with greater precision than existing approaches.

Ensocell raised $16.3 million in 2024 backed by OMX Ventures and Sofinnova Capital, with research operations based at the Wellcome Genome Campus in Hinxton and additional presence in Alameda, California. The company is targeting autoimmune, inflammatory, and fibrotic diseases where broad-spectrum immunosuppressants have failed patients.